Story

CAVA Stock Gains After Morgan Stanley Upgrades to Overweight

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
CAVA Stock Gains After Morgan Stanley Upgrades to Overweight

Summary

Shares of the Mediterranean fast-casual chain rose after Morgan Stanley upgraded its rating and price target, citing an attractive entry point following a recent stock decline.

Text size
Background

CAVA Group (NYSE: CAVA) shares climbed 3.6% in pre-market trading after analysts at Morgan Stanley upgraded the stock to Overweight from Equalweight. The firm also raised its price target on the restaurant chain to $90 from a previous $86.

Details of the Upgrade

The move by Morgan Stanley signals a more bullish stance on the fast-casual company's growth prospects and valuation. According to a report from Investing.com, the upgrade follows a period of significant underperformance for the stock, making its current price more attractive to the investment bank.

The new $90 price target suggests notable upside from its recent trading levels. This upgrade adds to an already constructive Wall Street consensus, which, according to the source, included 17 buy ratings, 9 holds, and 1 sell rating prior to the change.

Sample IUX Markets – In-articleAd

Market Context

The analyst's call comes after CAVA's stock had fallen significantly. The shares had declined approximately 19.9% over the past month and were trading well below their 52-week high of $98.79.

Monday's rally appears to be a company-specific event. The broader market provided a mildly positive backdrop, but there was no major news from fast-casual peers like Chipotle or Sweetgreen to suggest a sector-wide trend. The catalyst for the move was squarely attributed to the Morgan Stanley note, prompting investors to reassess the stock's value after its recent drop.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST